Intel, Microsoft, Meta Platforms, Pfizer, Tesla: Why These 5 Stocks Are On Investors' Radars Today
On Monday, major U.S. indices showed mixed results. The Dow Jones Industrial Average closed 0.5% higher at 41,622.08, while the S&P 500 edged up 0.1% to 5,633.09. Meanwhile, the Nasdaq fell by 0.5%, closing at 17,592.13.
These are the top stocks that gained the attention of retail traders and investors throughout the day:
Intel Corporation INTC
Intel shares surged by 6.36% to close at $20.91, after reports that the company could receive up to $3 billion in federal funding to produce semiconductors for U.S. military applications. The potential grant is part of the CHIPS and Science Act’s Secure Enclave program, which aims to secure a domestic supply of advanced chips critical for defense and intelligence purposes.
Microsoft Corporation MSFT
Microsoft shares saw a slight increase of 0.17% to close at $431.34. The tech giant announced a new share repurchase program worth up to $60 billion and declared a quarterly dividend of $0.83 per share, marking a 10% increase from the previous quarter.
See Also: Apple Shares Slide In Monday Premarket: What’s Souring Sentiment?
Meta Platforms Inc. META
Meta Platforms shares rose by 1.75% to close at $533.28. The company has decided to use U.K. Facebook and Instagram posts to train its AI systems, despite this practice being prohibited under EU privacy laws.
Pfizer Inc. PFE
Pfizer shares increased by 2.73% to close at $30.07. Ron DeSantis-governed Florida is raising concerns about the safety of the mRNA vaccines, pointing to potential risks such as myocarditis and postural orthostatic tachycardia syndrome (POTS), rare heart conditions.
Tesla Inc. TSLA
Tesla shares dropped by 1.54% to close at $226.74. Electric vehicle (EV) registrations in July in the U.S. reportedly marked an 18% increase as compared to the same month last year owing to the success of the Tesla Cybertruck.
Photo by Phongphan on Shutterstock
Prepare for the day’s trading with top premarket movers and news by Benzinga.
Read Next:
This story was generated using Benzinga Neuro and edited by Shivdeep Dhaliwal
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Leave a Reply